TLDR: Integrated DNA Technologies (IDT) and Profluent Bio have initiated a strategic collaboration to design and optimize next-generation enzymes, leveraging Profluent’s AI-driven protein design capabilities with IDT’s expertise in enzymology and genomics.
REDWOOD CITY, Calif. & EMERYVILLE, Calif. – Integrated DNA Technologies (IDT), a Danaher company and a global leader in genomics, and Profluent Bio, a pioneer in AI-first protein design, announced a strategic collaboration on October 21, 2025. This partnership aims to revolutionize the design and optimization of next-generation enzymes by combining Profluent’s advanced generative AI platform with IDT’s extensive expertise in enzymology and genomics.
The collaboration seeks to explore novel pathways for developing enzyme variants and is expected to streamline the process from in silico designs to ready-to-use biological tools, promising enhanced speed, scalability, and scientific impact. This initiative also reinforces IDT’s newly established innovation hub in the Bay Area, underscoring its dedication to pioneering synthesis technologies and accelerating advancements in oncology research.
Ajay Gannerkote, President of IDT, emphasized the significance of this collaboration, stating, “At IDT, we’ve built a strong enzyme engineering capability—innovating proprietary enzymes that have powered countless scientific breakthroughs. This collaboration with Profluent Bio represents a bold step forward in our strategic roadmap. By integrating Profluent’s AI-driven protein design with IDT’s enzymology and genomics expertise, we will unearth new possibilities across a broad range of critical applications, from epigenetics to cancer research and beyond.”
Ali Madani, PhD, founder and CEO of Profluent Bio, added, “Pairing Profluent’s AI with IDT’s world-class enzymology and manufacturing expertise is a powerful way to bring new capabilities to researchers and the industry. This partnership reflects our belief that AI-designed proteins can unlock step-changes in enzyme efficiency, precision, and manufacturability, without being constrained by what evolution has already tried.”
Profluent’s innovative approach is built upon foundational models, including the latest generation ProGen3, which are trained on the Profluent Protein Atlas—a curated dataset comprising billions of sequences. This robust training enables broad biological understanding and precise alignment with experimental data. The company has already demonstrated the real-world impact of its AI models through innovations such as OpenCRISPR-1™, recognized as the world’s first AI-generated gene editor.
IDT plans to utilize its robust enzyme development infrastructure, genomics expertise, and global manufacturing capabilities to rigorously test, validate, and scale Profluent-designed sequences. This will significantly fuel its new product innovation pipeline. As an operating company within Danaher, which is actively investing in AI for molecular design across its enterprise, IDT is uniquely positioned to expedite the translation of AI-driven designs into high-performance, production-ready enzymes. This commitment extends to enhancing the precision and speed of its bespoke next-generation sequencing, synthetic biology, and gene editing offerings.
Also Read:
- Austrian AI Firms OtterlyAI and newsrooms Forge Alliance for Generative Engine Optimization
- Syndigo Unveils New AI-Powered Solutions for Enhanced Product Experience and Agentic Commerce
Profluent, founded in 2022 and headquartered in Emeryville, CA, is an AI-first company dedicated to pushing the boundaries of de novo protein design to create new biological solutions. The company is supported by prominent investors including Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures. IDT, headquartered in Coralville, Iowa, employs over 1400 individuals and is a leading provider in genomics.
